Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma.
Simeone E, Gentilcore G, Giannarelli D, Grimaldi AM, Caracò C, Curvietto M, Esposito A, Paone M, Palla M, Cavalcanti E, Sandomenico F, Petrillo A, Botti G, Fulciniti F, Palmieri G, Queirolo P, Marchetti P, Ferraresi V, Rinaldi G, Pistillo MP, Ciliberto G, Mozzillo N, Ascierto PA. Simeone E, et al. Among authors: curvietto m. Cancer Immunol Immunother. 2014 Jul;63(7):675-83. doi: 10.1007/s00262-014-1545-8. Epub 2014 Apr 3. Cancer Immunol Immunother. 2014. PMID: 24695951 Free PMC article.
Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma.
Simeone E, Grimaldi AM, Festino L, Giannarelli D, Vanella V, Palla M, Curvietto M, Esposito A, Palmieri G, Mozzillo N, Ascierto PA. Simeone E, et al. Among authors: curvietto m. Oncoimmunology. 2017 Jan 19;6(3):e1283462. doi: 10.1080/2162402X.2017.1283462. eCollection 2017. Oncoimmunology. 2017. PMID: 28405510 Free PMC article.
A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation.
Simeone E, Scognamiglio G, Capone M, Giannarelli D, Grimaldi AM, Mallardo D, Madonna G, Curvietto M, Esposito A, Sandomenico F, Sabbatino F, Bayless NL, Warren S, Ong S, Botti G, Flaherty KT, Ferrone S, Ascierto PA. Simeone E, et al. Among authors: curvietto m. J Transl Med. 2021 Jan 6;19(1):17. doi: 10.1186/s12967-020-02680-7. J Transl Med. 2021. PMID: 33407577 Free PMC article. Clinical Trial.
Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy.
Grimaldi AM, Simeone E, Giannarelli D, Muto P, Falivene S, Borzillo V, Giugliano FM, Sandomenico F, Petrillo A, Curvietto M, Esposito A, Paone M, Palla M, Palmieri G, Caracò C, Ciliberto G, Mozzillo N, Ascierto PA. Grimaldi AM, et al. Among authors: curvietto m. Oncoimmunology. 2014 May 14;3:e28780. doi: 10.4161/onci.28780. eCollection 2014. Oncoimmunology. 2014. PMID: 25083318 Free PMC article.
Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapy.
Mozzillo N, Simeone E, Benedetto L, Curvietto M, Giannarelli D, Gentilcore G, Camerlingo R, Capone M, Madonna G, Festino L, Caracò C, Di Monta G, Marone U, Di Marzo M, Grimaldi AM, Mori S, Ciliberto G, Ascierto PA. Mozzillo N, et al. Among authors: curvietto m. Oncoimmunology. 2015 May 22;4(6):e1008842. doi: 10.1080/2162402X.2015.1008842. eCollection 2015 Jun. Oncoimmunology. 2015. PMID: 26155423 Free PMC article.
Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib.
Queirolo P, Spagnolo F, Picasso V, Spano L, Tanda E, Fontana V, Giorello L, Merlo DF, Simeone E, Grimaldi AM, Curvietto M, Del Vecchio M, Bruzzi P, Ascierto PA. Queirolo P, et al. Among authors: curvietto m. Oncotarget. 2016 Jul 13;9(15):12408-12417. doi: 10.18632/oncotarget.10589. eCollection 2018 Feb 23. Oncotarget. 2016. PMID: 29552321 Free PMC article.
Nivolumab for the treatment of small cell lung cancer.
Simeone E, Grimaldi AM, Festino L, Trojaniello C, Vitale MG, Vanella V, Curvietto M, Ascierto PA. Simeone E, et al. Among authors: curvietto m. Expert Rev Respir Med. 2020 Jan;14(1):5-13. doi: 10.1080/17476348.2020.1681977. Epub 2019 Oct 29. Expert Rev Respir Med. 2020. PMID: 31622114 Review.
Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy.
Montesarchio V, Parrela R, Iommelli C, Bianco A, Manzillo E, Fraganza F, Palumbo C, Rea G, Murino P, De Rosa R, Atripaldi L, D'Abbraccio M, Curvietto M, Mallardo D, Celentano E, Grimaldi AM, Palla M, Trojaniello C, Vitale MG, Million-Weaver SL, Ascierto PA. Montesarchio V, et al. Among authors: curvietto m. J Immunother Cancer. 2020 Aug;8(2):e001089. doi: 10.1136/jitc-2020-001089. J Immunother Cancer. 2020. PMID: 32784217 Free PMC article.
19 results